Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05255471RecruitingPhase 3
Olaparib after surgery for recurrent ovarian cancer
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
NaplesAges 18 years+ - NCT05263284RecruitingPhase 1
Study of 8-chloroadenosine plus venetoclax for relapsed or refractory AML
This trial tests a combination of two drugs, 8-chloroadenosine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT05266144Recruiting
Catheter ablation for non-valvular atrial fibrillation
This trial studies catheter ablation, a procedure that targets heart rhythm triggers, for people with atrial fibrillation (an irregular heartbeat). It may help improve rhythm control, but you must meet specific heart and testing requirements and avoid certain conditions.
Beijing, Beijing MunicipalityAges 18–80 - NCT05266807RecruitingPhase 3
Capsule fecal transplant to prevent C. difficile coming back
This study tests whether taking a capsule form of fecal microbiota transplant (FMT) can help adults with their first C. difficile infection—or a first relapse—get better and reduce repeat episodes. Participants also take specific antibiotics for C. difficile as part of the study process.
Basel, BaselAges 18 years+ - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05283044Recruiting
Precision medicine testing for advanced, hard-to-remove cancers
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
BayonneAges 18 years+ - NCT05286788RecruitingPhase 2
MEKTOVI for children with adamantinomatous craniopharyngioma
This Phase 2 trial tests MEKTOVI® to treat pediatric adamantinomatous craniopharyngioma (a type of brain tumor). It may help shrink or control the tumor after it has come back or grown again.
Aurora, ColoradoAges 1–39 - NCT05295212RecruitingPhase 2
Atezolizumab plus chemo before surgery for lung cancer
This trial studies whether adding atezolizumab (an immune medicine) to standard platinum-based chemotherapy before surgery can improve outcomes for operable stage II–IIIB non-small cell lung cancer. The goal is to shrink the tumor and increase the chance the cancer can be removed with better results.
Changsha, HunanAges 18 years+ - NCT05310643RecruitingPhase 2
Nivolumab and ipilimumab for bowel cancer resistant to anti-PD1
This Phase 2 study tests two immunotherapy medicines (nivolumab and ipilimumab) in people with metastatic colorectal cancer that has not responded to anti-PD1 treatment. It focuses on tumors with mismatch repair problems (dMMR) and/or high microsatellite instability (MSI).
BesançonAges 18 years+ - NCT05312255Recruiting
Non-drug help to improve quality of life in myeloma
This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.
Buffalo, New YorkAges 18 years+ - NCT05316129RecruitingPhase 1
Trial of your own engineered T cells for ovarian cancer
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
Tampa, FloridaAges 18 years+ - NCT05327933Recruiting
Preventing chronic bleeding from the brain’s covering after surgery
This trial looks at whether a procedure called middle meningeal artery embolization can help stop chronic subdural hematoma (slow bleeding/collection under the brain covering) from coming back after your first surgery. It studies an added endovascular treatment right after your operation to reduce recurrence.
Berlin, State of BerlinAges 18 years+ - NCT05328505Recruiting
Imaging-guided radiation for prostate cancer that came back
This trial tests whether a special scan (PSMA PET) can help doctors aim and adjust radiation more precisely when prostate cancer returns after surgery. It may help by increasing dose to areas that look involved while lowering dose to uninvolved pelvic areas.
London, OntarioAges 18 years+ - NCT05331911RecruitingPhase 4
Propofol anesthesia vs sevoflurane for liver tumor surgery
This study compares two types of general anesthesia—propofol-based total intravenous anesthesia versus sevoflurane inhaled anesthesia—during planned surgery to remove liver tumors. The goal is to see whether the anesthesia choice affects long-term outcomes after partial liver removal for hepatocellular carcinoma.
Kaohsiung CityAges 20–80 - NCT05337397Recruiting
Outpatient laser treatment for repeat low-grade bladder tumors
This trial tests an outpatient laser procedure to remove recurring low-grade, non-solid bladder tumors. It may help prevent or control tumor growth with treatment done outside the hospital, if you meet the tumor and health criteria.
AarhusAges 18 years+ - NCT05340491RecruitingPhase 3
Radiation plus immunotherapy for repeat nasopharyngeal cancer
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Guangzhou, GuangdongAges 18–70 - NCT05343572RecruitingEarly Phase 1
Stem cell treatment to improve abnormal uterine lining
This early-phase study tests whether mobilized stem cells from bone marrow can help women with certain abnormal uterine lining problems become healthier and possibly improve fertility. It’s aimed at people who are not pregnant and meet specific diagnoses and test results.
Orange, ConnecticutAges 18–40 - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05348291Recruiting
Ventilation tubes for babies with frequent ear infections
This trial studies whether placing ventilation (ear) tubes in very young children can reduce how often ear infections happen. It focuses on babies under 1 year old who have a high pattern of repeat ear infections.
LundAges 1–2 - NCT05363111RecruitingPhase 1
Testing a targeted radioactive drug for relapsed myeloma
This Phase 1 study tests a targeted radioactive medicine made from daratumumab plus a radioactive payload, aiming to treat multiple myeloma that has come back or doesn’t respond to treatment. It’s designed mainly to check safety and how the treatment works in people who have had several prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT05366179RecruitingPhase 1
Personalized CAR-T therapy for recurring brain tumor
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
Chapel Hill, North CarolinaAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05407519RecruitingPhase 2
Tislelizumab and sitravatinib after liver cancer surgery to prevent relapse
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Hefei, AnhuiAges 18–70 - NCT05415631Recruiting
AI helps detect bladder tumors during bladder exam
This study tests an artificial-intelligence (AI) system during real-time bladder evaluation to better spot bladder tumors. It may help your care team find tumors more accurately during diagnosis or follow-up.
AmiensAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,355 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.